Quince Therapeutics (QNCX) Expected to Release Quarterly Earnings on Wednesday

Quince Therapeutics (NASDAQ:QNCX) is expected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Quince Therapeutics to announce earnings of ($1.3850) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, beating the consensus estimate of ($28.02) by $15.71. On average, analysts expect Quince Therapeutics to post ($8.39) EPS for the current fiscal year and ($3.63) EPS for the next fiscal year.

Quince Therapeutics Stock Performance

QNCX opened at $31.73 on Wednesday. Quince Therapeutics has a 1-year low of $15.10 and a 1-year high of $909.98. The company has a market capitalization of $32.27 million, a PE ratio of -0.20 and a beta of 1.33. The firm’s 50 day simple moving average is $30.68 and its two-hundred day simple moving average is $54.44.

Analysts Set New Price Targets

QNCX has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $70.00 target price on shares of Quince Therapeutics in a research report on Tuesday, August 18th. Wall Street Zen downgraded Quince Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Zacks Research raised Quince Therapeutics to a “hold” rating in a research report on Thursday, October 1st. Oppenheimer began coverage on Quince Therapeutics in a research note on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price objective for the company. Finally, Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research note on Thursday, September 24th. They set a “buy” rating and a $70.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $189.88.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company is advancing therapies designed to address underlying disease mechanisms and improve outcomes for patients with serious genetic and neurological disorders.

Quince’s lead program is based on the EryDex drug-delivery platform, which uses a patient’s own red blood cells to encapsulate and gradually release a corticosteroid in the body.